Bionano Genomics (BNGO) vs EyePoint (EYPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bionano Genomics (BNGO) has outperformed EyePoint (EYPT) over the past year, losing 49.2% versus a loss of 98.3%. Over five years, EYPT leads with a -98.6% price change compared with -100.0% for BNGO. EyePoint is the larger company by market cap ($26.6 million vs $11.5 million), about 2.3 times the size, while Bionano Genomics is growing revenue faster (-7.4% vs -27.5%).
Bionano Genomics converts more of its revenue into profit, with a net margin of -92.6% versus -739.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | EYPT |
|---|---|---|
| Share price | $0.8222 | $0.2342 |
| Market cap | $11.50M | $26.65M |
| 1-day change | -7.11% | -11.36% |
| YTD return | -46.26% | -98.72% |
| 1-year return | -49.25% | -98.29% |
| 5-year return | -99.97% | -98.58% |
| EPS (TTM) | $-1.96 | $-3.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $28.51M | $31.37M |
| Revenue growth (YoY) | -7.37% | -27.50% |
| Net income (latest FY) | $-26.39M | $-231.96M |
| Gross margin | 46.25% | — |
| Operating margin | -116.95% | -775.98% |
| Net margin | -92.59% | -739.42% |
| 52-week high | $2.23 | $19.11 |
| 52-week low | $0.81 | $0.2277 |
| Distance from 52-week high | -63.13% | -98.77% |
| Analyst consensus | none | buy |
| Avg. price target upside | +508.12% | +10963.19% |
| Average volume | 979.44K | 8.37M |
| Shares outstanding | 13.99M | 113.78M |
| Employees | 95 | 214 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EyePoint is about 2.3 times larger than Bionano Genomics by market value ($26.65M vs $11.50M).
- BNGO has outperformed EYPT by 49.0 percentage points over the past year.
- Bionano Genomics is more profitable, keeping -92.6 cents of every revenue dollar as net income versus -739.4 cents for EyePoint.
- Bionano Genomics grew revenue faster in its latest fiscal year (-7.37% vs -27.50%).
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
BNGO vs EYPT FAQ
Which is bigger, Bionano Genomics or EyePoint?
EyePoint (EYPT) is larger, with a market capitalization of $26.65M compared with $11.50M for Bionano Genomics (BNGO).
Which stock has performed better over the past year, BNGO or EYPT?
BNGO returned -49.25% over the past 12 months, compared with -98.29% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and EyePoint in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.